KPTI Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Myelofibrosis Regulatory ProgressThe myelofibrosis sNDA creates a potentially important expansion for selinexor beyond its current indications. Priority Review, if granted, could accelerate regulatory feedback, while the filing provides a defined catalyst that may broaden the addressable market and strengthen future revenue potential.
Strong Phase III Clinical EvidenceThe SENTRY results provide meaningful clinical support for the combination’s efficacy, including rapid and sustained spleen volume reduction and a favorable survival signal. This evidence can improve the probability of regulatory success and support physician adoption if the treatment receives approval.
Established Commercial FoundationExisting XPOVIO sales, patient support infrastructure, and coverage across community and academic settings give Karyopharm a commercial base for ongoing monetization. Reaffirmed guidance and modest product growth also indicate that the current franchise remains an operating platform for future expansion.
Bears Say
Severe Liquidity And Default RiskThe missed debt payment and short funding runway create an immediate threat to business continuity. Forbearance temporarily limits creditor remedies but does not eliminate overdue obligations, leaving Karyopharm dependent on new capital or strategic transactions to continue operations and fund its programs.
Persistent Losses And Stressed Capital StructureLarge ongoing losses and negative free cash flow show that the business is not yet self-funding, while negative equity and substantial debt reduce financial flexibility. This combination increases reliance on external financing, constrains investment choices, and makes future operations more vulnerable to funding disruption.
Pipeline Diversification SetbackFailure of the endometrial cancer trial narrows the development portfolio and increases reliance on XPOVIO’s existing business and the myelofibrosis opportunity. Reduced investment may conserve resources, but it also limits the number of independent growth drivers available to offset setbacks elsewhere.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is CHF22.86M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 28 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Aug 13, 2026. The company reported -CHF1.94 earnings per share for the quarter, missing the consensus estimate of -CHF1.148 by -CHF0.793.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -0.79.
How many shares outstanding does Karyopharm Therapeutics have?
Currently, no data Available
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -CHF1.94 in its last earnings report, missing expectations of -CHF1.148. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in CH:KPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
KPTI Company Deck
KPTI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed materially positive clinical and regulatory progress—most notably compelling Phase III SENTRY data, constructive FDA interactions around SVR35 as a surrogate endpoint, an on-track sNDA submission, publication/presentation of results, and steady XPOVIO commercial performance—positioning the company for a potential accelerated approval and a sizeable myelofibrosis market opportunity. Offsetting these positives are significant near-term financial risks: a missed endometrial cancer Phase III endpoint that reduced pipeline diversification, a widened reported net loss driven by non-cash financing impacts, limited cash runway (liquidity into September 2026) and an upcoming $15.8M loan payment that could trigger a covenant default without new financing or waivers. Regulatory timing uncertainty (need for long-term OS confirmatory data) and transitional expense pressures add further near-term risk. Overall, the call balanced strong clinical momentum and commercial readiness against pronounced short-term financial and execution risks.View all CH:KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
―Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―